Is this biotech built for steady growth?
Incyte is a biotechnology company that develops and commercializes prescription medicines. Its business is built around selling its therapies and continuing to advance a pipeline of additional products. The company operates at a scale that places it among larger public biotech firms by market value. Shares trade on Nasdaq.
Are margins and cash flow holding firm?
FundamentalsFor 2025, reported in USD, revenue reached about USD 5.1 billion, alongside EBIT of roughly USD 1.5 billion and net income of about USD 1.3 billion. Revenue grew 21.2% year over year, while trailing margins stayed elevated, with a 92.97% gross margin and a 26.71% net profit margin.
Cash generation, using the provided proxy, was about USD 1.17 billion, helped by modest depreciation and amortization of USD 93.3 million and capital spending of USD 58.9 million. The balance sheet shows USD 3.1 billion of cash; total debt was not disclosed.
Is the market discounting its balance sheet strength?
DCF / MultiplesAt USD 114.88, the stock trades below the DCF-derived fair value range implied by the scenario set. That setup is paired with a 16.02 trailing P/E and 11.91 EV/EBITDA, which indicate a business priced for restraint rather than one already valued for aggressive outcomes.
Conservative but cash rich
TakeawayThe price looks conservative against the cash-heavy balance sheet. The case works if cash generation stays durable. It also needs margins to remain structurally high. The risk is profitability fades faster than the valuation assumes. Another risk is cash gets spent without sustaining earnings power.